Cg Asset Management Has Trimmed Ligand Pharmaceuticals (LGND) Stake; Bel Fuse (BELFB) Sentiment Is 1.74

May 16, 2017 - By Louis Casey

Cg Asset Management Llc decreased Ligand Pharmaceuticals Inc (LGND) stake by 74.25% reported in 2016Q4 SEC filing. Cg Asset Management Llc sold 8,810 shares as Ligand Pharmaceuticals Inc (LGND)’s stock 0.00%. The Cg Asset Management Llc holds 3,055 shares with $310,000 value, down from 11,865 last quarter. Ligand Pharmaceuticals Inc now has $2.43 billion valuation. The stock increased 0.51% or $0.58 during the last trading session, reaching $114.65. About 197,040 shares traded or 3.24% up from the average. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) has risen 6.00% since April 16, 2017 and is uptrending. It has underperformed by 4.65% the S&P500.

Bel Fuse Inc. designs, manufactures and markets a range of products that power, protect and connect electronic circuits. The company has market cap of $287.97 million. The Company’s products include magnetic solutions, power solutions and protection, and connectivity solutions. It has a 7.71 P/E ratio. The Company’s operating divisions are North America, Asia and Europe.

Analysts await Bel Fuse, Inc. (NASDAQ:BELFB) to report earnings on July, 26.

The stock increased 1.06% or $0.25 during the last trading session, reaching $23.9. About 37,629 shares traded or 27.88% up from the average. Bel Fuse, Inc. (NASDAQ:BELFB) has risen 6.00% since April 16, 2017 and is uptrending. It has underperformed by 4.65% the S&P500.

Since January 1, 0001, it had 0 insider buys, and 1 insider sale for $149,685 activity.

Perritt Capital Management Inc holds 0.75% of its portfolio in Bel Fuse, Inc. for 100,177 shares. Thomson Horstmann & Bryant Inc owns 168,202 shares or 0.64% of their US portfolio. Moreover, Investors Asset Management Of Georgia Inc Ga Adv has 0.3% invested in the company for 13,075 shares. The California-based Wall Street Associates has invested 0.24% in the stock. Polaris Capital Management Llc, a Massachusetts-based fund reported 96,000 shares.

Investors sentiment increased to 1.2 in 2016 Q4. Its up 0.12, from 1.08 in 2016Q3. It improved, as 23 investors sold LGND shares while 85 reduced holdings. 39 funds opened positions while 91 raised stakes. 22.77 million shares or 1.00% less from 23.00 million shares in 2016Q3 were reported. Rk Capital Mngmt Ltd Liability Corp, Colorado-based fund reported 191,883 shares. Pnc Fincl Grp invested in 13,808 shares. Parkside Bancorporation holds 0% or 10 shares. Ubs Asset Management Americas Inc owns 128,568 shares. Cornerstone Management Ltd Liability Corp holds 3,371 shares or 0% of its portfolio. Alpine Woods Capital Investors Ltd Liability Co holds 0.02% or 3,284 shares. Clearbridge Limited Liability Company invested 0.19% of its portfolio in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Blackrock Japan Company Ltd accumulated 185 shares. The New York-based Etrade Cap Limited Liability Corp has invested 0.04% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). 1492 Management Ltd Limited Liability Company accumulated 10,064 shares. Farmers & Merchants Invs Incorporated has invested 0% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Bessemer Gp invested 0% in Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Metropolitan Life Insurance Ny holds 13,548 shares or 0.01% of its portfolio. Jw Asset Limited Com accumulated 2.44% or 36,086 shares. 1,332 were accumulated by Jpmorgan Chase Company.

Since November 22, 2016, it had 0 insider buys, and 6 insider sales for $11.09 million activity. On Wednesday, March 8 HIGGINS JOHN L sold $428,240 worth of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) or 4,000 shares. The insider Aryeh Jason sold 37,247 shares worth $4.13M. FOEHR MATTHEW W had sold 6,879 shares worth $711,214.

Among 5 analysts covering Ligand Pharmaceuticals (NASDAQ:LGND), 4 have Buy rating, 1 Sell and 0 Hold. Therefore 80% are positive. Ligand Pharmaceuticals had 12 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was initiated by Stephens with “Overweight” on Wednesday, April 13. The rating was maintained by Roth Capital on Thursday, November 19 with “Buy”. Roth Capital maintained the stock with “Buy” rating in Friday, March 11 report. The rating was downgraded by Deutsche Bank to “Sell” on Friday, August 5. On Friday, December 18 the stock rating was maintained by Roth Capital with “Buy”. Roth Capital maintained Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Monday, September 21 with “Buy” rating. The stock of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) earned “Buy” rating by Roth Capital on Thursday, September 3. The rating was maintained by TH Capital on Friday, December 18 with “Buy”. The firm has “Buy” rating by TH Capital given on Wednesday, September 30. The rating was maintained by Roth Capital on Wednesday, September 30 with “Buy”.